Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: The Hippo signaling pathway comprises mammalian sterile 20-like kinase 1/2, large tumor suppressor 1/2, and Yes-associated protein 1 (YAP1). This study investigated phosphorylated YAP (pYAP, Ser 127) protein expression in oral squamous cell carcinoma (OSCC).
Patients And Methods: Tissues from patients with oral epithelial dysplasia (OED, n=7), carcinoma (CIS, n=14), and OSCC (n=109) were analyzed.
Results: Cytoplasmic expression of pYAP was low in OED, CIS, and OSCC tissues. The expression of pYAP was correlated with differentiation, and the expression of low levels of YAP was significantly more common in well-differentiated to moderately differentiated OSCC than in poorly differentiated OSCC. High pYAP expression correlates with characteristics of epithelial-to-mesenchymal transition (EMT), , loss of E-cadherin and increased expression of vimentin and laminin 5 (<0.0001). Additionally, the protein arginine methyltransferase 1, a positive modulatory factor of YAP activity, was found to be correlated with elevated levels of pYAP expression (<0.0007).
Conclusion: The presence of elevated pYAP expression may serve as a prognostic indicator of an aggressive OSCC with EMT during the invasive stage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17743 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential YAP-1/FOSL-1 silencing and epigenetic therapy to overcome stromal barriers in pancreatic cancer.
Int J Pharm
September 2025
CINBIO, Immunology Group, Universidade de Vigo 36310 Vigo, Spain; Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive malignancy with poor therapeutic outcomes due to its desmoplastic tumor microenvironment (TME), hindering drug and activated immune cell penetration. Cancer-associated fibroblasts (CAFs) are central in supporting tumor growth and forming a protective stroma. We propose a novel dual-therapy targeting the Hippo pathway and histone deacetylation, both involved in tumor progression, resistance, and stromal interactions, to overcome PDAC therapeutic resistance.
View Article and Find Full Text PDFPurpose: Combinatorial therapies are essential for treating advanced non-small cell lung cancer (NSCLC), particularly overcoming resistance to third-generation epidermal growth factor receptor (EGFR) like osimertinib (OSI). The Hippo signaling pathway, a critical regulator of cell proliferation, apoptosis, and tumor progression, is often dysregulated in NSCLC and contributes to chemo-resistance. This study investigated the potential of epigallocatechin-3-gallate (EGCG), a green tea polyphenol, to overcome OSI resistance by modulating the Hippo signaling pathway, specifically through inhibition of the YAP-1 (Yes-associated protein)-TEAD (TEA domain transcription factor)-CTGF (connective tissue growth factor) axis.
View Article and Find Full Text PDFTargeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells.
Gastric Cancer
September 2025
Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: The tyrosine kinase inhibitor (TKI) imatinib targets KIT and PDGFRA, offering significant therapeutic benefits in advanced gastrointestinal stromal tumors (GISTs). However, the high rate of recurrence following treatment discontinuation suggests that drug-tolerant persister cells (DTPs) may contribute to therapy resistance. Elucidating the mechanisms underlying DTP survival is critical for the development of curative strategies.
View Article and Find Full Text PDFVerteporfin Mitigates Isoproterenol-Induced Myocardial Hypertrophy by Attenuating IL-6/STAT3 in Cardiac Fibroblasts.
Cardiovasc Ther
September 2025
Department of Cardiac Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yes-associated protein (YAP) is a major downstream nuclear coactivator of the Hippo pathway and is activated during myocardial hypertrophy. Verteporfin, a YAP inhibitor, may serve as a potential treatment for myocardial hypertrophy. This study was aimed at exploring the role and underlying mechanisms of verteporfin in isoproterenol (ISO)-induced myocardial hypertrophy both in vivo and in vitro.
View Article and Find Full Text PDFVerteporfin inhibits the cGAS-STING pathway and improves the tumor microenvironment during cisplatin treatment in hepatocellular carcinoma.
Front Immunol
September 2025
Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, China.
Background: Cisplatin (DDP) is a clinical first-line chemotherapy drug for hepatocellular carcinoma (HCC), but treatment is often ineffective due to drug resistance. Yes-associated protein 1 (YAP1) is a critical regulator/factor in HCC tumor progression. Our previous research showed that DDP promoted the expression of YAP1 in mice bearing H22 cell in situ liver tumors, which might be related to the poor therapeutic effect of DDP.
View Article and Find Full Text PDF